Return to Listing

1 result(s) for BAY 73-4506 (regorafenib)

PI Name Protocol # Title
Willscott Naugler IRB00009526 A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080

You may qualify for additional trials within our Phase 1 Program